

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number
WO 01/23389 A3

(51) International Patent Classification⁷: C07D 487/04.
A61K 31/519, 31/437, 31/4365, 31/47, 31/44, A61P 9/00,
25/00, C07D 471/04, 473/34, 215/46, 213/73, 239/48,
471/14, 495/04, 475/08, G01N 33/566 // (C07D 487/04,
239:00, 209:00) (C07D 471/04, 235:00, 221:00) (C07D
487/04, 239:00, 231:00) (C07D 471/04, 249:00, 221:00)
(C07D 471/14, 221:00, 221:00, 209:00) (C07D 471/14,
239:00, 221:00, 209:00)

(71) Applicants (for all designated States except US): NEURO-
GEN CORPORATION [US/US]; 35 Northeast Industrial
Road, Branford, CT 06405 (US). PFIZER, INC. [US/US];
235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HORVATH, Ray-
mond, F. [US/US]; 973 Little Meadow, Guilford, CT
06437 (US). TRAN, Jennifer [US/US]; 56 Barrier Hill
Drive, Guilford, CT 06437 (US). DE LOMBAERT,
Stephane [US/US]; 37 Concord Drive, Madison, CT
06443 (US). HODGETTS, Kevin, Julian [US/US];
224 Reservoir Road, Killingworth, CT 06443 (US).
CARPINO, Philip, A. [US/US]; 50 Meridian Street,
Groton, CT 06340 (US). GRIFFITH, David, A. [US/US];
10 Barley Hill Road, Old Saybrook, CT 06475 (US).

(21) International Application Number: PCT/US00/26886

(22) International Filing Date:
29 September 2000 (29.09.2000)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
60/156,870 30 September 1999 (30.09.1999) US

(74) Agents: RICHARDS, John; Ladas & Parry, 26 West 61st
Street, New York, NY 10023 et al. (US).


[Continued on next page]

(54) Title: CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES



(57) Abstract: The present invention also provides a general method to whereby mono-, bi-, or tri-cyclic heterocycles may be modified to obtain potent antagonists at the NPY₁ receptor. The present invention provides novel, potent, non-peptidic antagonists of NPY receptors, particularly, the NPY₁ receptors, designed from a selection of mono-, bi-, or tri-cyclic heterocyclic cores. This invention relates to novel compounds, compositions, and methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. The novel compounds encompassed by the present invention are those of the formula (I-XV).

WO 01/23389 A3



(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
10 May 2002

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/US 00/26886

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04 A61K31/519 A61K31/437 A61K31/4365 A61K31/47
 A61K31/44 A61P9/00 A61P25/00 C07D471/04 C07D473/34
 C07D215/46 C07D213/73 C07D239/48 C07D471/14 C07D495/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 03510 A (DU PONT MERCK PHARMA) 29 January 1998 (1998-01-29) claims 1,66 ---	1, 47
A	WO 99 38868 A (DU PONT PHARM CO) 5 August 1999 (1999-08-05) claims 1,7 ---	1, 47
A	WO 99 40091 A (AMGEN INC) 12 August 1999 (1999-08-12) claims 1,26 -----	1, 47

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

11 June 2001

Date of mailing of the international search report

22/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/US 00/26886

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D475/08 G01N33/566 //(C07D487/04,239:00,209:00),
(C07D471/04,235:00,221:00), (C07D487/04,239:00,231:00),
(C07D471/04,249:00,221:00), (C07D471/14,221:00,209:00),

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

11 June 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/26886

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 (C07D471/14, 239:00, 221:00, 209:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

11 June 2001

Date of mailing of the international search report

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1- 71 (in part)

Present claims 1 to 71 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds where R4 is a phenyl radical substituted as claimed in claim 1 and R5R6N-A-B-N(R2)- represents -NH-CH₂-CH₂-NH- as illustrated in all examples of the description.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/26886

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9803510 A	29-01-1998	AU 3894297 A	10-02-1998
		BR 9710544 A	17-08-1999
		CA 2259583 A	29-01-1998
		CN 1225637 A	11-08-1999
		CZ 9900184 A	17-11-1999
		EP 0915880 A	19-05-1999
		HR 970413 A	31-10-1998
		LT 99008 A, B	27-03-2000
		LV 12292 A	20-06-1999
		LV 12292 B	20-11-1999
		NO 990264 A	10-03-1999
		PL 331523 A	19-07-1999
		SI 9720045 A	31-10-1999
		US 6136809 A	24-10-2000
		US 6060478 A	09-05-2000
		US 6124289 A	26-09-2000
		ZA 9706603 A	25-01-1999
WO 9938868 A	05-08-1999	US 6191131 B	20-02-2001
		US 6060478 A	09-05-2000
		AU 2478799 A	16-08-1999
		BR 9908206 A	05-12-2000
		CN 1289335 T	28-03-2001
		EP 1049699 A	08-11-2000
WO 9940091 A	12-08-1999	US 6187777 B	13-02-2001
		AU 2659099 A	23-08-1999
		EP 1054887 A	29-11-2000

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/20488 A2

(51) International Patent Classification⁷: **C07D 215/00**

(21) International Application Number: **PCT/EP01/10014**

(22) International Filing Date: **30 August 2001 (30.08.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
00119262.4 6 September 2000 (06.09.2000) EP

(71) Applicant: **F. HOFFMANN-LA ROCHE AG [CH/CH];**
124 Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors: **BREU, Volker; 9a Leonhard-Mueller-Strasse,**
79418 Schliengen (DE). DAUTZENBERG, Frank;
75 Vogesenstrasse, 79379 Muelheim (DE). GUERRY,
Philippe; In den Holeematten 2, CH-4102 Binningen
(CH). NETTEKOVEN, Matthias, Heinrich; Bandweg
10, 79639 Grenzach-Wyhlen (DE). PFLIEGER, Philippe;
1, rue du Vignoble, F-68130 Schwoben (FR).

(74) Agent: **WITTE, Hubert; 124 Grenzacherstrasse,**
CH-4070 Basle (CH).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **QUINOLINE AND QUINAZOLINE DERIVATIVES**

WO 02/20488 A2




(I)

(57) Abstract: Compounds of formula (I) as well as pharmaceutically usable salts, solvates and esters thereof, wherein R¹, R², R³, R⁴, A¹ and A² have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

Quinoline and quinazoline derivatives

The present invention is concerned with novel quinoline and quinazoline derivatives useful as neuropeptide Y (NPY) receptor ligands, particularly neuropeptide Y (NPY) antagonists.

5 The invention is concerned especially with compounds of formula I



I

wherein

R¹ is alkyl, cycloalkyl, aralkyl or trifluoroalkyl;

10 R² is hydrogen, alkyl, alkoxy, hydroxy, halogen, trifluoroalkyl, difluoroalkoxy or trifluoroalkoxy;

R³ is aryl or heteroaryl;

R⁴ is hydrogen;

R⁵ is hydrogen, alkyl or aralkyl;

15 R⁶ and R⁷ are each independently hydrogen or alkyl;

Wb/12.07.01

A¹ is CH or N;

A² is a 4- to 10- membered heterocyclic ring optionally substituted with alkyl, hydroxy, alkoxy, alkoxyalkyl, alkoxyalkoxy, hydroxyalkoxy, -COOR⁵ or -CONR⁶R⁷;

and pharmaceutically usable salts, solvates and esters thereof.

- 5 The compounds of formula I and their pharmaceutically usable salts and are novel and have valuable pharmacological properties. They are neuropeptide ligands, for example neuropeptide receptor antagonists and in particular, they are selective neuropeptides Y Y5 receptor antagonists.

10 Neuropeptide Y is a 36 amino acid peptide that is widely distributed in the central and peripheral nervous systems. This peptide mediates a number of physiological effects through its various receptor subtypes. Studies in animals have shown that neuropeptide Y is a powerful stimulus of food intake, and it has been demonstrated that activation of neuropeptide Y Y5 receptors results in hyperphagia and decreased thermogenesis. Therefore compounds that antagonise neuropeptide Y at the Y5 receptor subtype represent
15 an approach to the treatment of eating disorders such as obesity and hyperphagia.

 The current approach is aiming at medical intervention to induce weight loss or prevention of weight gain. This is achieved by interfering with appetite control, which is mediated by the Hypothalamus, an important brain region proven to control food intake. Herein, neuropeptide Y (NPY) has been proven to be one of the strongest central
20 mediators of food intake in several animal species. Increased NPY levels result in profound food intake. Various receptors of neuropeptide Y (NPY) have been described to play a role in appetite control and weight gain. Interference with these receptors is likely to reduce appetite and consequently weight gain. Reduction and long-term maintenance of body weight can also have beneficial consequences on con associated risk factors such as
25 arthritis, cardiovascular diseases, diabetes and renal failure.

 Accordingly, the compounds of formula I can be used in the prophylaxis or treatment of of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.

30 Objects of the present invention are the compounds of formula I and their aforementioned salts per se and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically usable salts and

solvates, the use of the said compounds, solvates and salts for the prophylaxis and/or therapy of illnesses, especially in the treatment or prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders such as hyperphagia and particularly obesity, and the use of the said compounds and salts for the production of
5 medicaments for the treatment or prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.

In the present description the term "alkyl", alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly preferred
10 a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched C₁-C₈ alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, preferably methyl and ethyl and most preferred methyl.

The term "cycloalkyl", alone or in combination, signifies a cycloalkyl ring with 3 to 8
15 carbon atoms and preferably a cycloalkyl ring with 3 to 6 carbon atoms. Examples of C₃-C₈ cycloalkyl are cyclopropyl, methyl-cyclopropyl, dimethylcyclopropyl, cyclobutyl, methyl-cyclobutyl, cyclopentyl, methyl-cyclopentyl, cyclohexyl, methyl-cyclohexyl, dimethyl-cyclohexyl, cycloheptyl and cyclooctyl, preferably cyclopropyl and particularly cyclopentyl.

The term "alkoxy", alone or in combination, signifies a group of the formula alkyl-
20 O- in which the term "alkyl" has the previously given significance, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec. butoxy and tert.butoxy, 2-hydroxyethoxy, 2-methoxyethoxy preferably methoxy and ethoxy and most preferred methoxy.

The term "alkoxyalkoxy", alone or in combination, signifies a group of the formula
25 alkyl-O-alkyl-O- in which the term "alkyl" has the previously given significance. A preferred example is 2-methoxyethoxy.

The term "hydroxyalkoxy", alone or in combination, signifies alkoxy group as previously described in which one hydrogen atom has been replaced by a hydroxy group. Examples are hydroxymethoxy and preferably 2-hydroxyethoxy.

30 The term "aryl", alone or in combination, signifies a phenyl or naphthyl group which optionally carries one or more, particularly one to three substituents each independently selected from halogen, trifluoromethyl, amino, alkyl, alkoxy, aryloxy, alkylcarbonyl, cyano, carbamoyl, alkoxycarbamoyl, methylenedioxy, carboxy, alkoxycarbonyl, aminocarbonyl,

alkylaminocarbonyl, dialkylaminocarbonyl, hydroxy, nitro and the like, such as phenyl, chlorophenyl, trifluoromethylphenyl, chlorofluorophenyl, aminophenyl, methylcarbonylphenyl, methoxyphenyl, methylenedioxyphenyl, 1-naphthyl and 2-naphthyl. Preferred is phenyl. Preferred substituents of phenyl and naphthyl are halogen, trifluoromethyl, amino, alkoxy, methylenedioxy, alkylcarbonyl, cyano, alkyl, nitro, hydroxy, trifluoromethoxy, alkylsulfanyl, alkenyl, alkoxycarbonyl, aryloxy, alkoxycarbonylamino, alkylcarbonylamino and aminocarbonyl.

The term "aralkyl", alone or in combination, signifies an alkyl or cycloalkyl group as previously defined in which one hydrogen atom has been replaced by an aryl group as previously defined. Preferred are benzyl, benzyl substituted with hydroxy, alkoxy or halogen, preferably fluorine. Particularly preferred is benzyl.

The term "heterocyclyl", alone or in combination, signifies a saturated, partially unsaturated or aromatic 4- to 10-membered heterocycle which contains one or more, preferably one or two hetero atoms selected from nitrogen, oxygen and sulfur, wherein oxygen and particularly nitrogen are preferred. If desired, it can be substituted on one or more carbon atoms by halogen, alkyl, alkoxy, oxo etc. and/or on a secondary nitrogen atom (i.e. -NH-) by alkyl, cycloalkyl, aralkoxycarbonyl, alkanoyl, phenyl or phenylalkyl or on a tertiary nitrogen atom (i.e. =N-) by oxido, with halogen, alkyl, cycloalkyl and alkoxy being preferred. Examples of such heterocyclyl groups are pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl, 3,4-dihydro-1H-isoquinolinyl or azepanyl, wherein each of these rings can be substituted with alkyl. Particularly preferred are pyrrolidinyl, piperidinyl, morpholinyl, 4-methyl-piperazinyl, 3,4-dihydro-1H-isoquinolinyl or azepanyl.

The term "heteroaryl", alone or in combination, signifies aromatic 5- to 10-membered heterocycle which contains one or more, preferably one or two hetero atoms selected from nitrogen, oxygen and sulfur, wherein nitrogen or oxygen are preferred. If desired, it can be substituted on one or more, preferably on one to three carbon atoms e.g. by halogen, trifluoromethyl, amino, alkoxy, methylenedioxy, alkylcarbonyl, cyano, alkyl, nitro, hydroxy, trifluoromethoxy, alkylsulfanyl, alkenyl, alkoxycarbonyl, aryloxy, alkoxycarbonylamino, alkylcarbonylamino or aminocarbonyl. Examples of such heteroaryl groups are thiophenyl, pyridinyl, pyrazinyl and pyrimidinyl, benzofuryl, 1H-indolyl, benzothiophenyl, and benzothiofuranlyl. Preferred are thiophenyl, pyridinyl, pyrimidinyl, 1H-indolyl.

The term "amino", alone or in combination, signifies a primary, secondary or tertiary amino group bonded via the nitrogen atom, with the secondary amino group

carrying an alkyl or cycloalkyl substituent and the tertiary amino group carrying two similar or different alkyl or cycloalkyl substituents or the two nitrogen substituents together forming a ring, such as, for example, -NH₂, methylamino, ethylamino, dimethylamino, diethylamino, methyl-ethylamino, pyrrolidin-1-yl or piperidino etc.,
5 preferably amino, dimethylamino and diethylamino and particularly primary amino.

The term "halogen" signifies fluorine, chlorine, bromine or iodine and preferably fluorine, chlorine or bromine and particularly fluorine or chlorine.

The term "carboxy", alone or in combination, signifies a -COOH group.

The term "cyano", alone or in combination, signifies a -CN group.

10 The term "nitro", alone or in combination, signifies a -NO₂ group.

The term "carboxyalkyl" alone or in combination, signifies an alkyl group as previously described in which one hydrogen atom has been replaced by a carboxy group. The carboxymethyl group is preferred and particularly carboxyethyl.

15 The term "trifluoroalkyl" alone or in combination, signifies an alkyl group as previously described in which three hydrogen atoms have been replaced by three fluorine atoms. A preferred example is trifluoromethyl.

The term "difluoroalkoxy" alone or in combination, signifies an alkoxy group as previously described in which two hydrogen atoms have been replaced by two fluorine atoms. Examples are -O-CHF₂ and -O-CH₂CHF₂.

20 The term "trifluoroalkoxy" alone or in combination, signifies an alkoxy group as previously described in which three hydrogen atoms have been replaced by three fluorine atoms. Examples are -O-CF₃, -O-CH₂CF₃. Preferred is -O-CF₃.

Examples of pharmaceutically usable salts of the compounds of formula I are salts with physiologically compatible mineral acids such as hydrochloric acid, sulfuric acid or
25 phosphoric acid; or with organic acids such as methanesulfonic acid, acetic acid, trifluoroacetic acid, citric acid, fumaric acid, maleic acid, tartaric acid, succinic acid or salicylic acid. Preferred is formic acid. The compounds of formula I with free carboxy groups can also form salts with physiologically compatible bases. Examples of such salts are alkali metal, alkali earth metal, ammonium and alkylammonium salts such as the Na,
30 K, Ca or tetramethylammonium salt. The compound of formula I can also be present in the form of zwitterions.

The compounds of formula I can also be solvated, e.g. hydrated. The solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I (hydration). The term pharmaceutically usable salts also includes pharmaceutically usable
5 solvates.

The term pharmaceutically usable esters of the compounds of formula I means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile
10 ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.

15 In more detail, for example, the COOH groups of compounds according to formula I can be esterified. The alkyl and aralkyl esters are examples of suitable esters. The methyl, ethyl, propyl, butyl and benzyl esters are preferred esters. The methyl and ethyl esters are especially preferred. Further examples of pharmaceutically usable esters are compounds of formula I, wherein the hydroxy groups can be esterified. Examples of such esters are
20 formate, acetate, propionate, butyrate, isobutyrate, valerate, 2-methylbutyrate, isovalerate and N,N-dimethylaminoacetate. Preferred esters are acetate and N,N-dimethylaminoacetate.

The term "lipase inhibitor" refers to compounds which are capable of inhibiting the action of lipases, for example gastric and pancreatic lipases. For example orlistat and
25 lipstatin as described in U.S. Patent No. 4,598,089 are potent inhibitor of lipases. Lipstatin is a natural product of microbial origin, and orlistat is the result of a hydrogenation of lipstatin. Other lipase inhibitors include a class of compound commonly referred to as panclicins. Panclicins are analogues of orlistat (Mutoh et al, 1994). The term "lipase inhibitor" refers also to polymer bound lipase inhibitors for example described in
30 International Patent Application WO99/34786 (Geltex Pharmaceuticals Inc.). These polymers are characterized in that they have been substituted with one or more groups that inhibit lipases. The term "lipase inhibitor" also comprises pharmaceutically acceptable salts of these compounds. The term "lipase inhibitor" preferably refers to orlistat.

Orlistat is a known compound useful for the control or prevention of obesity and
35 hyperlipidemia. See, U.S. Patent No. 4,598,089, issued July 1, 1986, which also discloses

processes for making orlistat and U.S. Patent No. 6,004,996, which discloses appropriate pharmaceutical compositions. Further suitable pharmaceutical compositions are described for example in International Patent Applications WO 00/09122 and WO 00/09123. Additional processes for the preparation of orlistat are disclosed in European Patent
5 Applications Publication Nos. 185,359, 189,577, 443,449, and 524,495.


Orlistat is preferably orally administered from 60 to 720 mg per day in divided doses two to three times per day. Preferred is wherein from 180 to 360 mg, most preferably 360 mg per day of a lipase inhibitor is administered to a subject, preferably in divided doses two or, particularly, three times per day. The subject is preferably an obese or overweight
10 human, i.e. a human with a body mass index of 25 or greater. Generally, it is preferred that the lipase inhibitor be administered within about one or two hours of ingestion of a meal containing fat. Generally, for administering a lipase inhibitor as defined above it is preferred that treatment be administered to a human who has a strong family history of obesity and has obtained a body mass index of 25 or greater.

Orlistat can be administered to humans in conventional oral compositions, such as, tablets, coated tablets, hard and soft gelatin capsules, emulsions or suspensions. Examples of carriers which can be used for tablets, coated tablets, dragées and hard gelatin capsules are lactose, other sugars and sugar alcohols like sorbitol, mannitol, maltodextrin, or other fillers; surfactants like sodium lauryl sulfate, Brij 96, or Tween 80; disintegrants
20 like sodium starch glycolate, maize starch or derivatives thereof; polymers like povidone, crospovidone; talc; stearic acid or its salts and the like. Suitable carriers for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like. Moreover, the pharmaceutical preparations can contain preserving agents, solubilizers, stabilizing agents, wetting agents, emulsifying agents, sweetening agents,
25 coloring agents, flavoring agents, salts for varying the osmotic pressure, buffers, coating agents and antioxidants. They can also contain still other therapeutically valuable substances. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods known in the pharmaceutical art. Preferably, orlistat is administered according to the formulation shown in the Examples and in U.S. Patent No.
30 6,004,996, respectively.

The compounds of formula I can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for

example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.

In the nomenclature used in the present application the ring atoms of the quinoline and the quinazoline rings are numbered as follows:



wherein, R^4 is attached at the 8-position. In a preferred embodiment of the present invention R^3 is attached at the 5- or 6-position. In a particularly preferred embodiment of the present invention R^3 is attached at the 7-position of the quinoline or quinazoline ring.

In another preferred embodiment of the invention R^2 is attached at the 7-position and particularly preferred at the 5- or 6-position.

Preferred are compounds according to formula I and pharmaceutically usable salts and solvates thereof.

Also preferred are compounds of formula I, wherein R^2 is hydrogen, alkyl, alkoxy, hydroxy, trifluoroalkyl, difluoroalkoxy or trifluoroalkoxy. Particularly preferred compounds of formula I are those, wherein R^2 is hydrogen, methyl, methoxy, ethoxy, fluoro, chloro, $-O-CHF_2$ or $-O-CF_3$. Most preferred is hydrogen.

Another preferred aspect of the present invention are compounds according to formula I, wherein R^1 is alkyl. Particularly preferred is ethyl and most preferred is methyl.

Likewise preferred are compounds of formula I, wherein A^1 is CH.

Other preferred compounds of formula I are those, wherein A^1 is N.

Further preferred are compounds according to formula I, wherein R^3 is unsubstituted phenyl, thiophenyl, pyridinyl, pyrimidinyl, 1H-indolyl, benzofuryl, benzothiophenyl or naphthyl or R^3 is phenyl, thiophenyl, pyridinyl, pyrimidinyl, 1H-indolyl, benzofuryl, benzothiophenyl or naphthyl, substituted with one to three substituents each independently selected from halogen, trifluoromethyl, amino, alkoxy, methylenedioxy, alkylcarbonyl, cyano, alkyl, nitro, hydroxy, trifluoromethoxy,

alkylsulfanyl, alkenyl, alkoxycarbonyl, aryloxy, alkoxycarbonylamino, alkylcarbonylamino and aminocarbonyl.

Further preferred are compounds according to formula I, wherein R^3 is unsubstituted thiophenyl, pyridinyl or naphthyl or R^3 is phenyl or thiophenyl substituted
5 with one or two substituents each independently selected from halogen, trifluoromethyl, alkoxy, alkylcarbonyl, cyano and hydroxy.

Particularly preferred are compounds according to formula I, wherein R^3 is unsubstituted thiophenyl, pyridinyl or naphthyl or R^3 is phenyl or thiophenyl substituted
10 with one or two substituents each independently selected from fluoro, chloro, trifluoromethyl, methoxy, methylcarbonyl, cyano and hydroxy.

Also preferred are compounds according to formula I, wherein R^3 is phenyl or phenyl substituted with one to three substituents, preferably one, each independently
selected from halogen, trifluoromethyl, amino, alkoxy, methylenedioxy, alkylcarbonyl and
cyano or R^3 is thiophenyl, pyridinyl, pyrimidinyl, 1H-indolyl or benzofuryl. Particularly
15 preferred are these compounds, wherein R^3 is phenyl or phenyl substituted with fluoro, chloro, trifluoromethyl, primary amino, methoxy, ethoxy, methylcarbonyl and/or ethylcarbonyl or R^3 is thiophenyl, pyridinyl, pyrimidinyl or 1H-indolyl. Most preferred are these compounds, wherein R^3 is phenyl or phenyl substituted with chloro, trifluoromethyl, primary amino, methoxy, ethoxy and/or methylcarbonyl or R^3 is thiophenyl, pyridinyl,
20 pyrimidinyl or 1H-indolyl.

Also preferred compounds according to formula I are those, wherein A^2 is a 4- to 10-membered heterocyclic ring optionally substituted with alkyl. Particularly preferred are those compounds, wherein A^2 is a 5- to 7- membered monocyclic or a 10-membered bicyclic heterocyclic ring optionally substituted with alkyl.

25 Further preferred are these compounds, wherein A^2 is a pyrrolidine, piperidine, morpholine, piperazine, 3,4-dihydro-1H-isoquinoline or azepane ring, wherein these rings are optionally substituted with alkyl. Most preferred are these compounds, wherein A^2 is a pyrrolidine, piperidine, morpholine, 4-methyl-piperazine, 3,4-dihydro-1H-isoquinoline or azepane ring.

30 Also preferred are compounds according to formula I, wherein R^5 is hydrogen, methyl, ethyl or benzyl.

Further preferred are compounds of formula I, wherein R⁶ and R⁷ are hydrogen, methyl or ethyl.

Examples of preferred compounds of formula I are:

- 7-(3-Chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
- 5 2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline;
- 3-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenylamine;
- 1-[4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-ethanone;
- 2-methyl-7-phenyl-4-pyrrolidin-1-yl-quinoline;
- 7-(4-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
- 10 2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-yl-quinoline;
- 2-methyl-7-pyridin-3-yl-4-pyrrolidin-1-yl-quinoline;
- 2-methyl-7-pyrimidin-5-yl-4-pyrrolidin-1-yl-quinoline;
- 2-methyl-4-piperidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline;
- 7-(3-chloro-phenyl)-2-methyl-4-piperidin-1-yl-quinoline;
- 15 1-[4-(2-methyl-4-piperidin-1-yl-quinolin-7-yl)-phenyl]-ethanone;
- 3-(2-methyl-4-piperidin-1-yl-quinolin-7-yl)-phenylamine;
- 7-(4-methoxy-phenyl)-2-methyl-4-piperidin-1-yl-quinoline;
- 2-methyl-4-piperidin-1-yl-7-thiophen-2-yl-quinoline;
- 2-methyl-7-phenyl-4-piperidin-1-yl-quinoline;
- 20 7-(1H-indol-5-yl)-2-methyl-4-piperidin-1-yl-quinoline;
- 2-methyl-4-piperidin-1-yl-7-pyridin-3-yl-quinoline;
- 2-methyl-4-morpholin-4-yl-7-(3-trifluoromethyl-phenyl)-quinoline;
- 1-[4-(2-methyl-4-morpholin-4-yl-quinolin-7-yl)-phenyl]-ethanone;
- 2-methyl-4-(4-methyl-piperazin-1-yl)-7-(3-trifluoromethyl-phenyl)-quinoline;

- 4-(3,4-dihydro-1H-isoquinolin-2-yl)-2-methyl-7-(3-trifluoromethyl-phenyl)-quinoline;
- 5-(3-chloro-phenyl)-2-methyl-4-piperidin-1-yl-quinoline;
- 2-methyl-4-piperidin-1-yl-5-(3-trifluoromethyl-phenyl)-quinoline;
- 5 5-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
- 5-(3-chloro-phenyl)-2-methyl-4-morpholin-4-yl-quinoline;
- 4-azepan-1-yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinoline;
- 6-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
- 7-(3-chloro-phenyl)-4-pyrrolidin-1-yl-quinoline;
- 10 2-methyl-4-piperidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinazoline;
- 7-(4-methoxy-phenyl)-2-methyl-4-piperidin-1-yl-quinazoline;
- 3-(2-methyl-4-piperidin-1-yl-quinazolin-7-yl)-phenylamine;
- 2-methyl-4-piperidin-1-yl-7-pyridin-3-yl-quinazoline;
- 2-methyl-7-pyrimidin-5-yl-4-pyrrolidin-1-yl-quinazoline;
- 15 2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinazoline;
- 7-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline;
- 7-(3-chloro-phenyl)-2-methyl-4-piperidin-1-yl-quinazoline;
- 4-azepan-1-yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinazoline;
- 7-(4-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline;
- 20 2-methyl-4-pyrrolidin-1-yl-7-thiophen-3-yl-quinazoline;
- [4-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-carbamic acid tert-butyl ester;
- 3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-benzonitrile;
- 7-(3,5-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline;

- 1-[3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-ethanone;
2-methyl-4-pyrrolidin-1-yl-7-(4-trifluoromethyl-phenyl)-quinazoline;
2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-yl-quinazoline;
1-[5-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-thiophen-2-yl]-ethanone;
5 7-(1H-indol-5-yl)-2-methyl-4-pyrrolidin-1-yl-quinazoline;
N-[2-methyl-4-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-acetamide;
2-methyl-7-(3-nitro-phenyl)-4-pyrrolidin-1-yl-quinazoline;
3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenylamine;
3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenol;
10 2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethoxy-phenyl)-quinazoline;
2-methyl-7-phenyl-4-pyrrolidin-1-yl-quinoline;
7-(4-ethyl-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
7-(3,4-dimethoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
7-(2,6-difluoro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
15 7-(2,4-dimethoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-methyl-4-pyrrolidin-1-yl-7-(4-trifluoromethyl-phenyl)-quinoline;
2-methyl-7-(4-methylsulfanyl-phenyl)-4-pyrrolidin-1-yl-quinoline;
7-(2-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
7-(3-ethoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
20 N-[3-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-acetamide;
2-methyl-4-pyrrolidin-1-yl-7-(4-trifluoromethoxy-phenyl)-quinoline;
7-benzo[1,3]dioxol-5-yl-2-methyl-4-pyrrolidin-1-yl-quinoline;
7-benzofuran-2-yl-2-methyl-4-pyrrolidin-1-yl-quinoline;

- 7-benzo[b]thiophen-2-yl-2-methyl-4-pyrrolidin-1-yl-quinoline;
7-(3-chloro-4-fluoro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
1-[5-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-thiophen-2-yl]-ethanone;
7-(3,4-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
5 7-(2-fluoro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-methyl-7-naphthalen-1-yl-4-pyrrolidin-1-yl-quinoline;
7-(2-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-methyl-4-pyrrolidin-1-yl-7-(4-vinyl-phenyl)-quinoline;
7-(3,5-bis-trifluoromethyl-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
10 7-(3-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
3-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-benzoic acid ethyl ester;
4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-benzoic acid ethyl ester;
2-methoxy-4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol;
N-[4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-acetamide;
15 dimethyl-[4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-amine;
7-(3,5-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-methyl-7-naphthalen-2-yl-4-pyrrolidin-1-yl-quinoline;
N-methyl-4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-benzamide;
3-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol;
20 2-methoxy-5-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol;
7-(2,6-dimethoxy-pyridin-3-yl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol;
2-methyl-7-(4-phenoxy-phenyl)-4-pyrrolidin-1-yl-quinoline;

7-(2,6-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethoxy-phenyl)-quinoline and
2-methyl-4-pyrrolidin-1-yl-7-(2-trifluoromethoxy-phenyl)-quinoline.

5 Examples of particularly preferred compounds of formula I are:

7-(3-Chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline;
1-[4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-ethanone;
7-(4-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
10 2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-yl-quinoline;
2-methyl-7-pyridin-3-yl-4-pyrrolidin-1-yl-quinoline;
2-methyl-4-piperidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline;
5-(3-chloro-phenyl)-2-methyl-4-piperidin-1-yl-quinoline;
4-azepan-1-yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinoline;
15 2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinazoline;
7-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline;
4-azepan-1-yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinazoline;
3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-benzonitrile;
1-[3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-ethanone;
20 7-(3-chloro-4-fluoro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
1-[5-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-thiophen-2-yl]-ethanone;
7-(3,4-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
2-methoxy-4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol;

- 15 -

7-(3,5-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline and
2-methyl-7-naphthalen-2-yl-4-pyrrolidin-1-yl-quinoline.


Further preferred compounds of the present invention are:

- 5 diethyl-[2-methyl-7-(3-trifluoromethyl-phenyl)-quinolin-4-yl]-amine;
[7-(3-amino-phenyl)-2-methyl-quinolin-4-yl]-diethyl-amine;
1-[4-(4-diethylamino-2-methyl-quinolin-7-yl)-phenyl]-ethanone;
and pharmaceutically usable salts, solvates and esters thereof.

- 10 Processes for the manufacture of compounds of formula I are an object of the invention.

The substituents and indices used in the following description of the processes have the significance given above unless indicated to the contrary.

Compounds of formula I




15

I


wherein R¹ to R⁴, A¹ and A² are defined as before can be prepared as follows:

According to scheme A compounds of formula I can be obtained by the reaction of a compound of the general formula IIIa with a compound of formula IIa. Alternatively, compounds of formula I can be prepared as shown in scheme B, wherein a compound of
20 formula IIIb is reacted in the presence of a compound of the formula IIb.

Scheme A



Scheme B



5

In both schemes, A and B, R^1 , R^2 , R^3 , R^4 , A^1 and A^2 are defined as before and Y and Z are substituents or groups which can be used in transition metal catalyzed cross coupling reactions. For example Y can be iodine, bromine, chlorine, methylsulfonyloxy, trifluoromethylsulfonyloxy, phenylsulfonyloxy or p-tosylsulfonyloxy and Z is for example
 10 $(OH)_2B-$ or $(R'O)_2B-$, wherein R' is methyl, ethyl, isopropyl or the two R' form together a cyclic diester such as 1,3-propyldioxy- or 2,3-dimethyl-2,3-butanedioxy-). (W. Thompson, J. Gaudino, J. Org. Chem. 1984, 49, 5237-5243; T. Ishiyama, M. Murata, N. Miyauro, J. Org. Chem. 1995, 60, 7508-7510). This reaction, also known as a "Suzuki coupling" (N. Miyauro and A. Suzuki, Chem. Rev. 1995, 95, 2457-2483), is preferably effected in an inert
 15 organic solvent such as e.g. dimethoxyethane, dioxan, dimethylformamide or tetrahydrofuran at a temperature between about 20°C and the boiling point of the reaction mixture. A further solvent or cosolvent is preferably added to the reaction mixture. Preferably, a base such an alkali metal carbonate, e.g. sodium carbonate, barium

hydroxide, potassium phosphate or potassium fluoride is preferably added as a solid or as an aqueous solution to the reaction mixture. Preferably, the reaction is performed in the presence of a transition metal complex such as a nickel or palladium metal complex, preferably a palladium complex such as tetrakis-triphenylphosphine-palladium or dichloro[1,1'-Bis(diphenylphosphino)-ferrocene]-palladium (II) dichloromethan.

Alternatively, substituent Z in scheme A or B can be


Sn(alkyl)_3 , e.g. $-\text{Sn}(\text{CH}_3)_3$ or $-\text{Sn}(\text{n-butyl})_3$ ("Stille reaction", J. K. Stille, Angew. Chem. 1986, 98, 504-519; S. P. Stanford, Tetrahedron, 1998, 54, 263-303); or

MgHal or Li ("Kharasch" reaction, D. A. Widdowson, Y.-Z. Zhang, Tetrahedron, 1986, 42, 211-2116); or

ZnHal , wherein Hal is bromine, iodine or chlorine; ("Negishi" reaction, E. I. Negishi, Acc. Chem. Res. 1982, 15, 340-348).


The reactions can be effected in the absence of a base in an inert solvent such as e.g. dimethoxyethane, dioxan or tetrahydrofuran at a temperature between about -20°C and the boiling point of the reaction mixture. It can also be advantageous to add an inert salt, especially lithium chloride. A transition metal complex such as a nickel or palladium metal complex, preferably a palladium metal complex can be present in the reaction mixture. A preferred palladium metal complex is tetrakis-triphenylphosphine-palladium.

The manufacture of the starting materials of formula III can be effected in a manner known per se, e.g. by reacting a 4-chloroquinoline of type IV or a 4-chloro-quinazoline of type IV with the corresponding amine of formula V



conveniently in a polar solvent in the presence of a proton binding reagent at a temperature between 20°C and the boiling point of the reaction mixture. It can be advantageous to add catalytic amounts of an iodide salt, preferably potassium iodide to the reaction mixture. Preferably used solvents are lower alkanol such as methanol or ethanol, isopropanol or n-butanol. Preferably, proton binding reagents are in excess of the amine


used in the reaction or an organic base such as triethylamin or pyridine or an inorganic base such as alkalimetal carbonates.



5

Compounds of formula IV in which R^1 , R^2 , R^4 , A^1 and Y have the above significance and can be prepared by reacting a compound of the general formula


10



with a halogenating agent, preferably phosphorous oxychloride, which may be used in excess as a solvent for the reaction. An aromatic dialkyl amine can also be used as a
 15 cosolvent. The reaction is effected at a temperature between 20°C and the boiling point of the reaction mixture, preferably between 50°C and 110°C. The aromatic dialkylamine is preferably N,N-dimethylaniline.

Compounds of formula VI, in which A^1 is CH, and Y, R^1 and R^2 have the above
 20 significance can be manufactured by reacting a compound of the general formula


- 19 -



VII

wherein R^1 , R^2 , R^4 and Y are defined as before and R^8 represents an alkyl group, preferably methyl or ethyl. This cyclisation reaction is preferably effected in an inert organic solvent such as diphenylether or Dowtherm^R A (Eutetic mixture of 26.5% of diphenyl and 73.5% of diphenylether) at a temperature between about 150°C and the boiling point of the reaction mixture in such a way that the alcohol formed during the reaction can be distilled out of the reaction mixture.


Compounds of formula VI, wherein A^1 is N, and Y, R^1 , R^2 and R^4 have the above significance can be prepared by reacting a compound of the general formula VIII



VIII

wherein R^2 , R^4 and Y are defined as before. This cyclisation reaction is preferably effected in an inert organic solvent such as absolute dimethylformamide by treating an intermediate VIII with an acylchlorid, preferably acetylchlorid (in the case of R^1 is CH_3) e.g. in the presence of an organic base, preferably triethylamine at a temperature between 0°C and 20°C for a short time, e.g. 20 minutes, followed by heating at 90°C for some hours, followed by treatment of the reaction mixture with an ammonium salt, preferably ammonium carbonate at a temperature between 20°C and 100°C. The cyclisation of the anthranilic acid VIII can also be effected by treating VIII in an acid anhydride, preferably acetyl anhydride in the case where R^1 is CH_3 , at a temperature between 20°C and boiling temperature of the reaction mixture, followed by treatment of the precipitated intermediate with anhydrous ammonia at temperature between -50°C and -25°C as described in J. Med. Chem. 1993, 36, 733-746.

Compounds of formula VII, in which R^1 , R^2 , R^4 , Y and R^8 have the above significance can be prepared by reacting a compound of general formula IX



IX

- 5 in which R^2 , R^4 and Y have the above significance with an appropriate substituted beta-ketoester. The reaction is preferably effected in an inert solvent, e.g. benzene, toluene or cyclohexane at boiling temperature of the reaction mixture. An organic acid, e.g. p-toluensulfonic acid or an inorganic acid, e.g. hydrochlorid acid can be used as a catalyst. The water which is formed during the reaction can be preferably separated from the
- 10 reaction mixture through azeotropic distillation with e.g. a Dean-Stark water separator. In another variant of the reaction, it is preferably effected in an inert solvent, e.g. benzene, toluene or cyclohexane at room temperature. An organic acid, e.g. p-toluensulfonic acid or an inorganic acid, e.g. hydrochloride acid can be used as a catalyst. The water which is formed during the reaction can be removed from the reaction mixture by treating the
- 15 reaction mixture with a water-trapping reagent, e.g. molecularsieve.


Compounds of formula VIII, in which R^2 and Y have the above significance can be prepared according to S. E. Webber et al. J. Med. Chem. 1993, 36, 733-746.

- The conversion of a compound of formula I into a pharmaceutically usable salt can
- 20 be carried out by treatment of such a compound with an inorganic acid, for example a hydrohalic acid, such as, for example, hydrochloric acid or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid etc., or with an organic acid, such as, for example, acetic acid, citric acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. The corresponding carboxylate salts can also be prepared from the
- 25 compounds of formula I by treatment with physiologically compatible bases.

A preferred process for the preparation of a compound of formula I comprises one of the following reactions:

- a) the reaction of a compound of formula

- 21 -




in the presence of a compound of formula



5 or

b) the reaction of a compound of formula



in the presence of a compound of formula



wherein R^1 , R^2 , R^3 , R^4 , A^1 and A^2 are defined as before and Y and Z are substituents which can be used in transition metal catalyzed cross coupling reactions. In a preferred aspect the reactions a) and b) are performed in the presence of a transition metal complex such as for example a nickel or palladium metal complex, preferably a palladium metal complex, particularly preferred tetrakis-triphenylphosphine-palladium.


In a further preferred embodiment of the reactions a) and b) Y is iodine, bromine, chlorine, methylsulfonyloxy, trifluoromethylsulfonyloxy, phenylsulfonyloxy or p-tosylsulfonyloxy and Z is $(OH)_2B-$ or $(R'O)_2B-$, wherein R' is methyl, ethyl, isopropyl or the two R' form together with the oxygen atoms attached to the boron atom a cyclic diester, preferably 1,3-propyldioxy- or 2,3-dimethyl-2,3-butanedioxy, or Z is $-Sn(alkyl)_3$.

- 22 -

preferably $-\text{Sn}(\text{CH}_3)_3$ or $-\text{Sn}(\text{n-butyl})_3$, or MgHal or Li or ZnHal , wherein Hal is bromine, iodine or chlorine. Particularly preferred are the above reactions a) and b), wherein Y is bromine. Also particularly preferred are the reactions a) and b), wherein Z is $(\text{OH})_2\text{B}-$ or $-\text{Sn}(\text{Me})_3$.

5

The invention also includes intermediates of formula X



wherein R^1 , R^2 , R^4 , A^1 and A^2 are defined as before and, wherein R^9 is iodine, bromine, chlorine, methylsulfonyloxy, trifluoromethylsulfonyloxy, phenylsulfonyloxy or p-tosylsulfonyloxy. Particularly preferred are the compounds of formula X, wherein R^9 is iodine or bromine.

10

Especially preferred intermediates of formula X are:

15

7-iodo-2-methyl-4-pyrrolidin-1-yl-quinoline;

7-iodo-2-methyl-4-piperidin-1-yl-quinoline;

diethyl-(7-iodo-2-methyl-quinolin-4-yl)-amine;

7-iodo-2-methyl-4-morpholin-4-yl-quinoline;

7-iodo-2-methyl-4-(4-methyl-piperazin-1-yl)-quinoline;

4-(3,4-dihydro-1H-isoquinolin-2-yl)-7-iodo-2-methyl-quinoline hydrochloride;

5-iodo-2-methyl-4-piperidin-1-yl-quinoline;

20

5-iodo-2-methyl-4-pyrrolidin-1-yl-quinoline;

5-iodo-2-methyl-4-morpholin-4-yl-quinoline;

4-azepan-1-yl-7-iodo-2-methyl-quinoline;

- 23 -

- 6-bromo-2-methyl-4-pyrrolidin-1-yl-quinoline;
7-bromo-4-pyrrolidin-1-yl-quinoline;
7-bromo-2-methyl-4-piperidin-1-yl-quinazoline;
7-bromo-2-methyl-4-pyrrolidin-1-yl-quinazoline;
5 4-azepan-1-yl-7-bromo-2-methyl-quinazoline;
4-azetidin-1-yl-7-bromo-2-methyl-quinazoline;
7-bromo-4-chloro-2-methyl-quinazoline;
4-chloro-5-iodo-2-methyl-quinoline;
6-bromo-4-chloro-2-methyl-quinoline;
10 7-bromo-2-methyl-3H-quinazolin-4-one;
3-(3-iodo-phenylamino)-but-2-enoic acid ethyl ester.

Further preferred intermediates of the present invention are:

- (7-bromo-2-methyl-quinazolin-4-yl)-dimethyl-amine;
15 (7-bromo-2-methyl-quinazolin-4-yl)-butyl-amine.

The compounds of formula I described above for use as therapeutically active substances are a further object of the invention.

- Also an object of the invention are compounds described above for the production
20 of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the NPY receptor, particularly for the production of medicaments for the prophylaxis and therapy of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.

- Likewise an object of the invention is a pharmaceutical composition containing a
25 compound of formula I described above and a therapeutically inert carrier. Preferred is this composition comprising further a therapeutically effective amount of a lipase

inhibitor. Particularly preferred is the above composition, wherein the lipase inhibitor is orlistat.

An object of the invention is also the use of the compounds described above for the production of medicaments, particularly for the treatment and prophylaxis of arthritis,
5 cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity.

A further object of the invention comprises compounds which are manufactured according to one of the described processes.

A further object of the invention is a method for the treatment and prophylaxis of
10 arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity whereby an effective amount of a compound described above is administered.

According to a further aspect of the invention there is provided a method of treatment of obesity in a human in need of such treatment which comprises
15 administration to the human a therapeutically effective amount of a compound according to formula I and a therapeutically effective amount of a lipase inhibitor, particularly preferred, wherein the lipase inhibitor is orlistat. Also subject of the present invention is the mentioned method, wherein the administration is simultaneous, separate or sequential.

A further preferred embodiment of the present invention is the use of a compound
20 of the formula I in the manufacture of a medicament for the treatment and prevention of obesity in a patient who is also receiving treatment with a lipase inhibitor, particularly preferred, wherein the lipase inhibitor is orlistat.

Assay Procedures

25

Cloning of mouse NPY5 receptor cDNAs:

The full-length cDNA encoding the mouse NPY5 (mNPY5) receptor was amplified from mouse brain cDNA using specific primers, designed based on the published sequence, and Pfu DNA-Polymerase (Stratagene). The amplification product was
30 subcloned into the mammalian expression vector pcDNA3 using Eco RI and XhoI

restriction sites. Positive clones were sequenced and one clone, encoding the published sequence was selected for generation of stable cell clones.

5

Stable transfection:

Human embryonic kidney 293 (HEK293) cells were transfected with 10 µg mNPY5 DNA using the lipofectamine reagent (Gibco BRL) according to the manufacturer's instruction. Two days after transfection, geneticin selection (1 mg/ml) was initiated and several stable clones were isolated. One clone was further used for pharmacological
10 characterization.

Radioligand competition binding:

Human embryonic kidney 293 cells (HEK293), expressing recombinant mouse NPY5-receptor (mNPY5) were broken by three freeze/thawing cycles in hypotonic Tris
15 buffer (5 mM, pH 7.4, 1 mM MgCl₂), homogenized and centrifuged at 72,000 x g for 15 min. The pellet was washed twice with 75 mM Tris buffer, pH 7.4, containing 25 mM MgCl₂ and 250 mM sucrose, 0.1 mM phenylmethylsulfonylfluoride and 0.1 mM 1,10-phenanthroline, resuspended in the same buffer and stored in aliquots at -80°C. Protein was determined according to the method of Lowry using bovine serum albumine (BSA) as
20 a standard.

Radioligand competition binding assays were performed in 250 µl 25 mM Hepes buffer (pH 7.4, 2.5 mM CaCl₂, 1 mM MgCl₂, 1 % bovine serum albumine, and 0.01 % NaN₃ containing 5 µg protein, 100 pM [¹²⁵I]labelled peptide YY (PYY) and 10 µL DMSO
25 containing increasing amounts of unlabelled test compounds. After incubation for 1 h at 22°C, bound and free ligand are separated by filtration over glass fibre filters. Non specific binding is assessed in the presence of 1 µM unlabelled PYY. Specific binding is defined as the difference between total binding and non specific binding. IC₅₀ values are defined as the concentration of antagonist that displaces 50 % of the binding of [¹²⁵I]labelled
30 neuropeptide Y. It is determined by linear regression analysis after logit/log transformation of the binding data.

Results obtained in the foregoing test using representative compounds of the invention as the test compounds are shown in the following table:

<u>Compound</u>	<u>IC₅₀</u>
7-(4-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline (example 1.6)	0.06 micro Molar
7-(1H-indol-5-yl)-2-methyl-4-piperidin-1-yl-quinoline (example 1.17)	0.10 micro Molar

5

Preferred compounds as described above have IC₅₀ values below 1000 nM; more preferred compounds have IC₅₀ values below 100 nM, particularly below 10 nM. Most preferred compounds have IC₅₀ values below 1 nM. These results have been obtained by using the foregoing test.

10 The compounds of formula I and their pharmaceutically usable salts, solvates and esters can be used as medicaments (e.g. in the form of pharmaceutical preparations). The pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of
15 suppositories). However, the administration can also be effected parentally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).

The compounds of formula I and their pharmaceutically usable salts, solvates and esters can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules. Lactose, corn
20 starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules.

Suitable adjuvants for soft gelatin capsules, are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.

Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.

Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.

- 5 Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.

Moreover, the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or
10 antioxidants. They can also contain still other therapeutically valuable substances.

In accordance with the invention the compounds of formula I and their pharmaceutically usable salts, solvates and esters can be used for the prophylaxis and treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. The dosage can vary in wide limits and will, of course, be
15 fitted to the individual requirements in each particular case. In general, in the case of oral administration a daily dosage of about 0.1 mg to 20 mg per kg body weight, preferably about 0.5 mg to 4 mg per kg body weight (e.g. about 300 mg per person), divided into preferably 1-3 individual doses, which can consist, for example, of the same amounts, should be appropriate. It will, however, be clear that the upper limit given above can be
20 exceeded when this is shown to be indicated.

The invention is illustrated hereinafter by Examples, which have no limiting character.

ExamplesExample 1.1:

Preparation of 7-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline:

- 5 A mixture of 1.5 g 7-iodo-2-methyl-4-pyrrolidin-1-yl-quinoline (Example 3.1), 256 mg tetrakis(triphenylphosphine) palladium and 30 ml Dimethoxyethane is stirred under argon for 15 min. 1.04 g 3-Chlorophenylboronic acid and 7 ml Ethanol are added. The resulting red solution is stirred for another 10 min. at room temperature and treated afterwards with 19 ml of a 2M aqueous solution of sodium carbonate. The mixture is
- 10 refluxed for 1.5 h under vigorous stirring. After the reaction is complete, the reaction mixture is concentrated on a rotary evaporator. The residue is taken up in 50 ml water and extracted twice with 50 ml ethyl acetate. The combined organic phases are washed with 50 ml saturated aqueous solution of sodium chloride, dried over magnesium sulfate and filtered. The filtrate is evaporated and the residue is chromatographed on silica gel
- 15 (eluent: Dichloromethane/Methanol 19:1 then 4:1). The pure fractions are combined and evaporated. 1.235g of 7-(3-Chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline are obtained as a colorless oil. MS (ISP): 323.3 (M+H)⁺.

The following compounds were prepared in analogy to Example 1.1.:

20

Example 1.2:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid there is obtained 2-Methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline as a yellowish foam. MS (ISP): 357.3 (M+H)⁺.

25

Example 1.3:

In analogy with Example 1.1) with 3-aminophenylboronic acid there is obtained 3-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenylamine as a beige foam. MS (EI): peaks at m/e: 303 (M⁺, 100%), 274 (14%), 260 (9%).

30

- 29 -

Example 1.4:

In analogy with Example 1.1) with 4-acetylphenylboronic acid there is obtained 1-[4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-ethanone as a slightly brown foam. MS (ISP): 331.3 (M+H)⁺.

5

Example 1.5:

In analogy with Example 1.1) with phenylboronic acid there is obtained 2-methyl-7-phenyl-4-pyrrolidin-1-yl-quinoline as a yellowish foam. MS (ISP): 289.3 (M+H)⁺.

10

Example 1.6:

In analogy with Example 1.1) with 4-methoxyphenylboronic acid there is obtained 7-(4-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline as a white foam. MS (ISP): 319.4 (M+H)⁺.

15

Example 1.7:

In analogy with Example 1.1) with 2-thiopheneboronic acid there is obtained 2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-yl-quinoline as a beige foam. MS (ISP): 295.3 (M+H)⁺.

20

Example 1.8:

In analogy with Example 1.1) with pyridine-3-boronic acid 1,3-propane-diol cyclic ester there is obtained 2-Methyl-7-pyridin-3-yl-4-pyrrolidin-1-yl-quinoline as a yellowish foam. MS (ISP): 290.3 (M+H)⁺.

25

Example 1.9:

In analogy with Example 1.1) with 5-pyrimidinylboronic acid (Chem. Scr. 1986, 26, 305-309) there is obtained 2-methyl-7-pyrimidin-5-yl-4-pyrrolidin-1-yl-quinoline as a light yellow solid. MS (ISP): 290.3 (M+H)⁺.

Example 1.10:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 2-methyl-4-piperidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline as a yellow foam. MS (ISP): 371.3 (M+H)⁺.

Example 1.11:

In analogy with Example 1.1) with 3-chlorophenylboronic acid and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 7-(3-chloro-phenyl)-2-methyl-4-piperidin-1-yl-quinoline as a yellow foam. MS (EI): peaks at m/e: 337 (M+, 45%), 335(100%), 279 (9%).

Example 1.12:

In analogy with Example 1.1) with 4-acetylphenylboronic acid and 7-Iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 1-[4-(2-methyl-4-piperidin-1-yl-quinolin-7-yl)-phenyl]-ethanone as a yellow foam. MS (ISP): 345.4 (M+H)⁺.

Example 1.13:

In analogy with Example 1.1) with 3-aminophenylboronic acid and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 3-(2-methyl-4-piperidin-1-yl-quinolin-7-yl)-phenylamine as a slightly brown solid. MS (EI): peaks at m/e: 317 (M+, 100%), 260 (8%), 234 (9%).

Example 1.14:

In analogy with Example 1.1) with 4-methoxyphenylboronic acid and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 7-(4-methoxy-phenyl)-2-methyl-4-piperidin-1-yl-quinoline as a slightly orange foam. MS (ISP): 333.3(M+H)⁺.

Example 1.15:

In analogy with Example 1.1) with 2-thiophenboronic acid and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 2-methyl-4-piperidin-1-yl-7-thiophen-2-yl-quinoline as a yellow solid. Mp. 122-123°C. MS (ISP): 309.2(M+H)⁺.

Example 1.16:

In analogy with Example 1.1) with phenylboronic acid and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 2-methyl-7-phenyl-4-piperidin-1-yl-quinoline as a yellow solid. Mp. 111-112°C. MS (EI): peaks at m/e: 302 (M⁺, 100%), 245 (12%), 219(10%).

Example 1.17:

In analogy with Example 1.1) with 1H-indol-5-ylboronic acid (Heterocycles, 1992, 34, 1169-1175) and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 7-(1H-Indol-5-yl)-2-methyl-4-piperidin-1-yl-quinoline as a slightly brown solid. MS (ISP): 342.3(M+H)⁺.

Example 1.18:

In analogy with Example 1.1) with pyridine-3-boronic acid 1,3-propanediol cyclic ester and 7-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.2) there is obtained 2-methyl-4-piperidin-1-yl-7-pyridin-3-yl-quinoline as a yellow foam. MS (ISP): 304.3(M+H)⁺.

Example 1.19:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and diethyl-(7-iodo-2-methyl-quinolin-4-yl)-amine (Example 3.3) there is obtained diethyl-[2-methyl-7-(3-trifluoromethyl-phenyl)-quinolin-4-yl]-amine as a colorless oil. MS (ISP): 359.2(M+H)⁺.

Example 1.20:

In analogy with Example 1.1) with 3-aminophenylboronic acid and diethyl-(7-iodo-2-methyl-quinolin-4-yl)-amine (Example 3.3) there is obtained [7-(3-amino-phenyl)-2-methyl-quinolin-4-yl]-diethyl-amine as a slightly orange oil. MS (ISP): 306.3(M+H)⁺.

Example 1.21:

In analogy with Example 1.1) with 4-acetylphenylboronic acid and diethyl-(7-iodo-2-methyl-quinolin-4-yl)-amine (Example 3.3) there is obtained 1-[4-(4-diethylamino-2-methyl-quinolin-7-yl)-phenyl]-ethanone as a slightly orange oil. MS (ISP): 333.3(M+H)⁺.

Example 1.22:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and 7-Iodo-2-methyl-4-morpholin-4-yl-quinoline (Example 3.4) there is obtained 2-methyl-4-morpholin-4-yl-7-(3-trifluoromethyl-phenyl)-quinoline as a yellow foam. MS (EI): peaks at m/e: 372 (M+, 100%), 314 (67%), 169(19%).

Example 1.23:

In analogy with Example 1.1) with 4-acetylphenylboronic acid and 7-iodo-2-methyl-4-morpholin-4-yl-quinoline (Example 3.4) there is obtained 1-[4-(2-methyl-4-morpholin-4-yl-quinolin-7-yl)-phenyl]-ethanone as a slightly red foam. MS (ISP): 347.3(M+H)⁺.

Example 1.24:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and 7-iodo-2-methyl-4-(4-methyl-piperazin-1-yl)-quinoline (Example 3.5) there is obtained 2-methyl-4-(4-methyl-piperazin-1-yl)-7-(3-trifluoromethyl-phenyl)-quinoline as an orange foam. MS (EI): peaks at m/e: 385(M+, 57%), 370 (19%), 42(100%).

Example 1.25:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-7-iodo-2-methyl-quinoline hydrochloride (Example 3.6) there is obtained 4-(3,4-dihydro-1H-isoquinolin-2-yl)-2-methyl-7-(3-trifluoromethyl-phenyl)-quinoline as a light-yellow foam. MS (ISP): 419.3(M+H)⁺.

Example 1.26:

In analogy with Example 1.1) with 3-chlorophenylboronic acid and 5-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.7) there is obtained 5-(3-chloro-phenyl)-2-methyl-4-piperidin-1-yl-quinoline as a colourless viscous oil. MS (EI): peaks at m/e: 336(M+, 100%), 307 (17%), 277(32%), 225 (49%).

Example 1.27:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and 5-iodo-2-methyl-4-piperidin-1-yl-quinoline (Example 3.7) there is obtained 2-methyl-4-piperidin-1-yl-5-(3-trifluoromethyl-phenyl)-quinoline as a yellow foam. MS (ISP): 371.4(M+H)⁺.

Example 1.28:

In analogy with Example 1.1) with 3-chlorophenylboronic acid and 5-iodo-2-methyl-4-pyrrolidin-1-yl-quinoline (Example 3.8) there is obtained 5-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline as a light-yellow amorphous solid. MS (ISP): 323.3(M+H)⁺.

Example 1.29:

In analogy with Example 1.1) with 3-chlorophenylboronic acid and 5-Iodo-2-methyl-4-morpholin-1-yl-quinoline (Example 3.9) there is obtained 5-(3-chloro-phenyl)-2-methyl-4-morpholin-4-yl-quinoline as a colorless viscous oil. MS (EI): peaks at m/e: 338(M+, 87%), 277(100%), 245 (37%).

Example 1.30:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and 4-azepan-1-yl-7-iodo-2-methyl-quinoline (Example 3.10) there is obtained 4-azepan-1-yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinoline as a yellowish foam. MS (ISP): 385.3 (M+H)⁺.

Example 1.31:

In analogy with Example 1.1) with 3-chlorophenylboronic acid and 6-bromo-2-methyl-4-pyrrolidin-1-yl-quinoline (Example 3.11) there is obtained 6-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline as a yellowish gum. MS (ISP): 323.3 (M+H)⁺.

Example 1.32:

In analogy with Example 1.1) with 3-chlorophenylboronic acid and 7-bromo-4-pyrrolidin-1-yl-quinoline (Example 3.12) there is obtained 7-(3-chloro-phenyl)-4-pyrrolidin-1-yl-quinoline as a beige amorphous solid. MS (ISP): 309.2 (M+H)⁺.

Example 2.1:

Preparation of 2-Methyl-4-piperidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinazoline:

In analogy with Example 1.1) with 3-trifluoromethylphenylboronic acid and 7-bromo-2-methyl-4-piperidin-1-yl-quinazoline (Example 4.1) there is obtained 2-methyl-4-piperidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinazoline as a light-yellow solid. MS (EI): peaks at m/e: 371(M⁺, 76%), 342 (100%), 288(57%).

25

Example 2.2:

In analogy with Example 1.1) with 4-methoxyphenylboronic acid and 7-bromo-2-methyl-4-piperidin-1-yl-quinazoline (Example 4.1) there is obtained 7-(4-methoxy-phenyl)-2-methyl-4-piperidin-1-yl-quinazoline as a light-yellow oil. MS (ISP): 434.3(M+H)⁺.

Example 2.3:

In analogy with Example 1.1) with 3-aminophenylboronic acid and 7-bromo-2-methyl-4-piperidin-1-yl-quinazoline (Example 4.1) there is obtained 3-(2-methyl-4-piperidin-1-yl-quinazolin-7-yl)-phenylamine as a light-yellow solid. MS (ISP): 319.4(M+H)⁺.

Example 2.4:

In analogy with Example 1.1) with pyridine-3-boronic acid 1,3-propanediol cyclic ester and 7-bromo-2-methyl-4-piperidin-1-yl-quinazoline (Example 4.1) there is obtained 2-methyl-4-piperidin-1-yl-7-pyridin-3-yl-quinazoline as a light-yellow solid. MS (ISP): 305.3(M+H)⁺.

Example 2.5:

In analogy with Example 1.1) with 5-Pyrimidinylboronic acid (Chem. Scr. 1986, 26, 305-309) and 7-bromo-2-methyl-4-pyrrolidin-1-yl-quinazoline (Example 4.2) there is obtained 2-methyl-7-pyrimidin-5-yl-4-pyrrolidin-1-yl-quinazoline as a light-yellow solid. MS (ISP): 292.3(M+H)⁺.

Example 2.6:

In analogy with example 1.1) with 3-trifluoromethylphenylboronic acid and 7-bromo-2-methyl-4-pyrrolidin-1-yl-quinazoline (Example 4.2) there is obtained 2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinazoline as a light-yellow foam. MS (ISP): 358.2(M+H)⁺.

Example 2.7:

In analogy with example 1.1) with 3-chlorophenyl boronic acid and 7-bromo-2-methyl-4-pyrrolidin-1-yl-quinazoline (Example 4.2) there is obtained 7-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline as a white solid. MS (ISP): 324.3(M+H)⁺.

Example 2.8:

In analogy with example 1.1) with 3-chlorophenyl boronic acid and 7-bromo-2-methyl-4-piperidin-1-yl-quinazoline (Example 4.1) there is obtained 7-(3-chloro-phenyl)-
5 2-methyl-4-piperidin-1-yl-quinazoline as a light-yellow solid. MS (ISP): 338.2(M+H)⁺.

Example 2.9:

In analogy with example 1.1) with 3-trifluoromethylphenylboronic acid and 4-azepan-1-yl-7-bromo-2-methyl-quinazoline (Example 4.3) there is obtained 4-azepan-1-
10 yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinazoline as an off-white amorphous solid. MS (ISP): 386.3(M+H)⁺.

Example 3.1:

Preparation of 7-iodo-2-methyl-4-pyrrolidin-1-yl-quinoline:

15 A suspension of 2g of 4-chloro-7-iodo-2-methyl-quinoline (European patent application EP 0497371, CA 143946-47-8) in 20 ml absolute ethanol is treated successively with 1.09 ml pyrrolidine, 0.2 ml pyridine and 50 mg potassium iodide under argon. The resulting mixture is refluxed for 24 h. The solvent is then distilled off. The residue is taken up in 50 ml water and basified to pH 12 with a 2N solution of sodium hydroxyde. The
20 solid is filtered upon precipitation and washed with 20 ml of water and 20 ml of diethylether. The final product is dried under vacuum yielding 1.95 g (87%) of 7-iodo-2-methyl-4-pyrrolidin-1-yl-quinoline as an off-white solid. Mp: 99-102°C. MS (EI): peaks at m/e: 338(M+, 100%), 296 (5%), 183(9%).

25

Example 3.2:

In analogy with Example 3.1) with 4-chloro-7-iodo-2-methyl-quinoline and piperidine there is obtained 7-iodo-2-methyl-4-piperidin-1-yl-quinoline as a light-yellowish solid. Mp. 124-126°C. MS (EI): peaks at m/e: 352(M+, 100%), 296 (4%), 269(5%).

30

- 37 -

Example 3.3:

In analogy with Example 3.1) with 4-chloro-7-iodo-2-methyl-quinoline and diethylamine in an autoclave for 120h at 150°C there is obtained diethyl-(7-iodo-2-methyl-quinolin-4-yl)-amine as a reddish oil. MS (EI): peaks at m/e: 339(M+, 100%), 325 (73%), 198(43%).

Example 3.4:

In analogy with Example 3.1) with 4-chloro-7-iodo-2-methyl-quinoline and morpholine there is obtained 7-iodo-2-methyl-4-morpholin-4-yl-quinoline as an off-white solid. Mp. 103-105°C. MS (EI): peaks at m/e: 354(M+, 100%), 296 (73%), 169(13%).

Example 3.5:

In analogy with Example 3.1) with 4-chloro-7-iodo-2-methyl-quinoline and N-methylpiperazine there is obtained 7-iodo-2-methyl-4-(4-methyl-piperazin-1-yl)-quinoline as a light-brownish solid. Mp. 92-94°C. MS (EI): peaks at m/e: 367(M+, 100%), 352 (38%), 310(11%).

Example 3.6:

In analogy with Example 3.1) with 4-chloro-7-iodo-2-methyl-quinoline and tetrahydroisoquinoline there is obtained 4-(3,4-dihydro-1H-isoquinolin-2-yl)-7-iodo-2-methyl-quinoline hydrochloride as a beige solid. Mp. > 230°C. MS (ISP): 401.3(M+H)⁺.

Example 3.7:

In analogy with Example 3.1) with 4-chloro-5-iodo-2-methyl-quinoline (Example 5.2) and piperidine there is obtained 5-iodo-2-methyl-4-piperidin-1-yl-quinoline as an orange oil. MS (ISP): 353.2(M+H)⁺.

- 38 -

Example 3.8:

In analogy to Example 3.1) with 4-chloro-5-iodo-2-methyl-quinoline and pyrrolidine there is obtained 5-iodo-2-methyl-4-pyrrolidin-1-yl-quinoline as a light-yellow solid. Mp. 97-99°C. MS (ISP): 339.1(M+H)⁺.

5

Example 3.9:

In analogy to Example 3.1) with 4-chloro-5-iodo-2-methyl-quinoline and morpholine there is obtained 5-iodo-2-methyl-4-morpholin-4-yl-quinoline as a yellow solid. Mp. 144-145°C. MS (ISP): 355.1(M+H)⁺.

10

Example 3.10:

In analogy with Example 3.1) with 4-chloro-7-iodo-2-methyl-quinoline and azepine there is obtained 4-azepan-1-yl-7-iodo-2-methyl-quinoline as a beige solid. Mp. > 90-93°C. MS (ISP): 367.1(M+H)⁺.

15

Example 3.11:

In analogy with Example 3.1) with 6-bromo-4-chloro-2-methyl-quinoline (Example 5.3) and pyrrolidine there is obtained 6-bromo-2-methyl-4-pyrrolidin-1-yl-quinoline as a beige solid. MS (ISP): 291.2(M+H)⁺.

20

Example 3.12:

In analogy with Example 3.1) with 7-bromo-4-chloro-quinoline (J. Amer. Chem. Soc. 1946, 68, 113-116) and pyrrolidine there is obtained 7-bromo-4-pyrrolidin-1-yl-quinoline as a beige solid. MS (ISP): 277.2(M+H)⁺.

25

Example 4.1:

Preparation of 7-bromo-2-methyl-4-piperidin-1-yl-quinazoline:

In analogy to Example 3.1) with 7-bromo-4-chloro-2-methyl-quinazoline (Example 5.1) and piperidine there is obtained 7-bromo-2-methyl-4-piperidin-1-yl-quinazoline as an amorphous yellow solid. MS (ISP): 306.2(M+H)⁺.

5

Example 4.2:

In analogy to Example 3.1) with 7-bromo-4-chloro-2-methyl-quinazoline (Example 5.1) and pyrrolidine there is obtained 7-bromo-2-methyl-4-pyrrolidin-1-yl-quinazoline as a yellow solid. Mp. 120-122°C. MS (ISP): 292.2(M+H)⁺.

10

Example 4.3:

In analogy to Example 3.1) with 7-bromo-4-chloro-2-methyl-quinazoline (Example 5.1) and azepine there is obtained 4-azepan-1-yl-7-bromo-2-methyl-quinazoline as an orange oil. MS (ISP): 320.3(M+H)⁺.

15

Example 4.4:

In analogy to Example 3.1) with 7-bromo-4-chloro-2-methyl-quinazoline (Example 5.1) and azetidine there is obtained 4-azetidin-1-yl-7-bromo-2-methyl-quinazoline as a light-brown solid. Mp. 129-131°C. MS (ISP): 278.1(M+H)⁺.

20

Example 4.5:

In analogy to Example 3.1) with 7-bromo-4-chloro-2-methyl-quinazoline (Example 5.1) and dimethylamine there is obtained (7-bromo-2-methyl-quinazolin-4-yl)-dimethylamine as a brown solid. Mp. 55-57°C. MS (ISP): 266.2(M+H)⁺.

25

Example 4.6:

In analogy to Example 3.1) with 7-bromo-4-chloro-2-methyl-quinazoline (Example 5.1) and n-butylamine there is obtained (7-bromo-2-methyl-quinazolin-4-yl)-butylamine as a beige solid. Mp. 133-135°C. MS (ISP): 294.2(M+H)⁺.

Example 5.1:

Preparation of 7-bromo-4-chloro-2-methyl-quinazoline:

A suspension of 0.45 g 7-bromo-2-methyl-3H-quinazolin-4-one in 0.48 ml N,N-dimethylaniline is treated with 1.41 ml phosphorous oxychloride and heated at 60°C for 2h. The reaction mixture is evaporated in vacuo and the residue is taken up with 20 ml water, neutralized with 10 ml saturated aqueous sodium bicarbonate and extracted with 25 ml dichloromethane twice. The organic layer is washed with 25 ml water, 25 ml brine, dried over magnesium sulfate and evaporated in vacuo. The residue is purified by chromatography on silica gel with Heptane/ethylacetate 2:1. 0.288 g (59%) of 7-bromo-4-chloro-2-methyl-quinazoline are obtained as an orange solid. Mp. >82°C (dec). MS (EI): peaks at m/e: 258(M+, 37%), 221 (100%), 179(9%).

Example 5.2:

Preparation of 4-chloro-5-iodo-2-methyl-quinoline

25 g of crude 3-(3-Iodo-phenylamino)-but-2-enoic acid ethyl ester (Example 7.1) is added rapidly to 25 ml boiling Dowtherm A, keeping the internal temperature above 250°C. After 1.5h of reaction time, the mixture is cooled at room temperature. The solid which separates is filtered, washed with 50 ml dichloromethane and dried in vacuo to obtain 17.27 g (83.6%) of a mixture of 7-iodo-2-methyl-quinolin-4-ol and 5-iodo-2-methyl-quinolin-4-ol.

To 17.27 g of the above product is added 20 ml phosphorous oxychloride. The resulting suspension is stirred at room temperature for 2 h. The crystalline product is triturated with 50ml dry diethylether and filtered. The cake is suspended in 50 ml ice water and concentrated ammonium hydroxide is added until the resulting suspension is permanently basic. The product is filtered, washed with 50 ml water and dried in vacuo. Purification of the crude product by chromatography on silica gel with Heptane/ethylacetate 2:1 gives 7.1g (41%) of 4-chloro-7-iodo-2-methyl-quinoline and 4.26g (23%) of 4-chloro-5-iodo-2-methyl-quinoline as a beige solid. Mp. 98-100°C. MS (EI): peaks at m/e: 303 (M+, 100%), 176 (100%), 140(21%).

Example 5.3:

In analogy with Example 5.1) with 6-bromo-4-hydroxy-2-methyl-quinoline (Synthesis, 1987, 482-483) there is obtained 6-Bromo-4-chloro-2-methyl-quinoline as a light-purple solid. MS (EI): peaks at m/e: 256(M+, 100%), 220 (13%), 141(20%).

5

Example 6.1:

Preparation of 7-bromo-2-methyl-3H-quinazolin-4-one:

To a solution of 0.81g 4-bromoanthranilic acid (J. Org. Chem. 1997, 62, 1240-1256), 39 mg 4-(dimethylamino)pyridine and 2.09 ml triethylamine in dry dimethylformamide is added dropwise 0.69 ml acetylchloride at 3°C for 20 min. in an ice-water bath under argon. The reaction mixture is then heated at 90°C for 3 h. and 1.08 g ammonium carbonate is added portionwise over 10 min., and the mixture is stirred at the same temperature for 1 h. After cooling, the mixture is poured onto 20 ml water and the precipitate is filtered, washed with water and dried in vacuo to give 0.46 g (51%) of crude 7-Bromo-2-methyl-3H-quinazolin-4-one as a light-brown solid. Mp. >191°C (dec.). MS (EI): peaks at m/e: 240(M+, 100%), 223 (14%), 197(18%).

15

Example 7.1:

Preparation of 3-(3-iodo-phenylamino)-but-2-enoic acid ethyl ester:

A mixture of 47.79 g 3-iodoaniline, 27.7 ml ethyl acetoacetate and 0.13 ml 37% hydrochloric acid in 65 ml benzene is boiled under a reflux condenser fitted with a water separator. After 4 h. 4 ml of water have been collected. The solvent is removed at reduced pressure and the residual oil dried in vacuo. 3-(3-iodo-phenylamino)-but-2-enoic acid ethyl ester is obtained as a light brown oil. MS (ISP): 332.1 (M+H)⁺.

25

Example 8.1

Preparation of 7-(4-Methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline; compound with formic acid:

To a solution of 44 mg (0.15 mmol) 7-Bromo-2-methyl-4-pyrrolidin-1-yl-quinazoline in 1.2 ml dioxane / dimethoxyethane 1:1 was added 57 mg (0.375 mmol) 4-methoxy-phenyl-

30

boronic acid in 0.4 ml ethanol; 7 mg (0.007 mmol) Dichloro[1,1'-Bis(diphenylphosphino)-ferrocene]-palladium (II) dichloromethan adduct, and 0.6 ml 2 M Na₂CO₃aq. and the mixture was heated to 85°C for 12 h. After filtration, the mixture was purified by reversed phase column chromatography eluting with an acetonitrile /
 5 water (formic acid) gradient yielding 17 mg (35%) of the title compound. MS m/e (%): 320.4 (M+H⁺, 100)

According to example 8.1 further quinazoline derivatives have been synthesised. The results are compiled in the following list comprising example 8.2 to example 8.15.

The isolated formiates 8.1-8.15 can each be transferred to the respective parent compound
 10 by treatment with base.

The examples 8.2-8.15 have each been synthesised from 7-Bromo-2-methyl-4-pyrrolidin-1-yl-quinazoline and the respective boronic acid or the 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-derivative thereof comprised in the following table:

<u>Ex.</u>	<u>Boronic acid or the 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-derivative thereof</u>	<u>Product Name</u>	<u>MH⁺ found</u>
8.2	4,4,5,5-Tetramethyl-2-thiophen-3-yl-[1,3,2]dioxaborolane (Lit.: WO 0027853A1)	2-Methyl-4-pyrrolidin-1-yl-7-thiophen-3-yl-quinazoline; compound with formic acid	296.4
8.3	[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-carbamic acid tert-butyl ester (Lit.: WO 0119829A2, CSIRO, Molecular Science, Clayton South VIC 3169, Australia)	[4-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-carbamic acid tert-butyl ester; compound with formic acid	405.5

8.4	3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzonitrile (Lit.: WO 9845265A1)	3-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-benzonitrile; compound with formic acid	315.4
8.5	3,5-Dichloro-benzeneboronic acid (commercially available)	7-(3,5-Dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline; compound with formic acid	359.3
8.6	3-Acetylphenylboronic acid (commercially available)	1-[3-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-ethanone; compound with formic acid	332.4
8.7	4-Trifluoromethylphenyl-boronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-(4-trifluoromethyl-phenyl)-quinazoline; compound with formic acid	358.4
8.8	Thiophene-2-boronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-thiophen-2-yl-quinazoline; compound with formic acid	296.4

8.9	5-Acety-2-thiopheneboronic acid (commercially available)	1-[5-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-thiophen-2-yl]-ethanone; compound with formic acid	338.4
8.10	5-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indole (Lit.: WO 0027853A1)	7-(1H-Indol-5-yl)-2-methyl-4-pyrrolidin-1-yl-quinazoline	329.4
8.11	N-[2-Methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (Lit.: WO 0027853A1)	N-[2-Methyl-4-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-acetamide; compound with formic acid	361.5
8.12	3-Nitrophenylboronic acid (commercially available)	Formic acid; 2-methyl-7-(3-nitro-phenyl)-4-pyrrolidin-1-yl-quinazoline	335.4
8.13	3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenylamine (WO 9831688A1)	3-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenylamine; compound with formic acid	305.4
8.14	3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol (commercially available)	3-(2-Methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenol; compound with formic acid	306.4

8.15	(3-Trifluoromethoxy)-benzeneboronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethoxy-phenyl)-quinazoline; compound with formic acid	374.4
------	--	--	-------

Example 9.1

2-Methyl-7-phenyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid:

To a solution of 43 mg (0.13 mmol) 7-Iodo-2-methyl-4-pyrrolidin-1-yl-quinoline in 1.2 ml dioxane / dimethoxyethane 1:1 was added 39.6 mg (0.325 mmol) phenyl-boronic acid, 6 mg (0.007 mmol) Dichloro[1,1'-Bis(diphenylphosphino)-ferrocene]palladium (II) dichloromethan adduct, and 0.55 ml 2M Na₂CO₃aq. and the mixture was heated to 85°C for 12 h. After filtration the mixture was purified by reversed phase column chromatography eluting with an acetonitrile/water (formic acid) gradient yielding 25 mg (57 %) of the title compound. MS m/e (%): 289.4 (MH⁺, 100)

According to example 9.1 further quinoline derivatives have been synthesised. The results are compiled in the following table No 2 comprising example 9.2 to example 9.39.

The isolated formiates 9.1-9.39 can each be transferred to the respective parent compound by treatment with base.

The examples 9.2-9.39 have each been synthesised from 7-Iodo-2-methyl-4-pyrrolidin-1-yl-quinoline and the respective boronic acid or the 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-derivative thereof comprised in the following starting material list.

<u>Ex.</u>	<u>Boronic acid or the 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl-derivative thereof</u>	<u>Product Name</u>	<u>MH⁺ found</u>
9.2	4-Ethylphenylboronic acid (commercially available)	7-(4-Ethyl-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	317.4
9.3	3,4-Dimethoxyphenylboronic acid (commercially available)	7-(3,4-Dimethoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	349.4
9.4	2,6-Difluorophenylboronic acid (commercially available)	7-(2,6-Difluoro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	325.4
9.5	2,4-Dimethoxyphenylboronic acid (commercially available)	7-(2,4-Dimethoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	349.4
9.6	4-Trifluoromethylboronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-(4-trifluoromethyl-phenyl)-quinoline; compound with formic acid	357.4

9.7	4-(Methylthio)-phenylboronic acid (commercially available)	2-Methyl-7-(4-methylsulfanyl-phenyl)-4-pyrrolidin-1-yl-quinoline; compound with formic acid	335.5
9.8	2-Methoxyphenylboronic acid (commercially available)	7-(2-Methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	319.4
9.9	3-Ethoxyphenylboronic acid (commercially available)	7-(3-Ethoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	333.4
9.10	3-Acetamidophenylboronic acid (commercially available)	N-[3-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-acetamide; compound with formic acid	346.4
9.11	4-Trifluoromethoxyboronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-(4-trifluoromethoxy-phenyl)-quinoline; compound with formic acid	373.4

9.12	(3,4-Methylenedioxyphenyl)boronic acid (commercially available)	7-Benzo[1,3]dioxol-5-yl-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	333.4
9.13	Benzo[B]furan-2-boronic acid (commercially available)	7-Benzofuran-2-yl-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	329.4
9.14	Benzo[B]thiophene-2-boronic acid (commercially available)	7-Benzo[b]thiophen-2-yl-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	345.5
9.15	3-Chloro-4-fluorophenylboronic acid (commercially available)	7-(3-Chloro-4-fluorophenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	341.8
9.16	5-Acetyl-thiopheneboronic acid (commercially available)	1-[5-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-thiophen-2-yl]-ethanone; compound with formic acid	337.5

9.17	3,4-Dichlorophenylboronic acid (commercially available)	7-(3,4-Dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	358.3
9.18	2-Fluorophenylboronic acid (commercially available)	7-(2-Fluoro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	307.4
9.19	1-Naphtaleneboronic acid (commercially available)	2-Methyl-7-naphthalen-1-yl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	339.5
9.20	2-Chlorophenylboronic acid (commercially available)	7-(2-Chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	323.8
9.21	4-Vinylphenylboronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-(4-vinyl-phenyl)-quinoline; compound with formic acid	315.4

9.22	3,5-Bis(trifluoromethyl)phenylboronic acid (commercially available)	7-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	425.4
9.23	3-Methoxyphenylboronic acid (commercially available)	7-(3-Methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	319.4
9.24	3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid ethyl ester (Lit.: WO 0027853A1)	3-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-benzoic acid ethyl ester; compound with formic acid	361.5
9.25	4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid ethyl ester (commercially available)	4-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-benzoic acid ethyl ester; compound with formic acid	361.5

9.26	2-Methoxy-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol (Lit.: WO 0027853A1)	2-Methoxy-4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol; compound with formic acid	335.4
9.27	N-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-acetamide (commercially available)	N-[4-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-acetamide; compound with formic acid	346.4
9.28	Dimethyl-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-amine (Lit.: J. Org. Chem. 2000, 65, 164-168)	Dimethyl-[4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-amine; compound with formic acid	332.5
9.29	3,5-Dichlorophenylboronic acid (commercially available)	7-(3,5-Dichlorophenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	358.3
9.30	2-Naphtaleneboronic acid (commercially available)	2-Methyl-7-naphthalen-2-yl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	339.5

9.31	N-Methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzamide (Lit.: WO 9845265A1)	N-Methyl-4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-benzamide; compound with formic acid	346.4
9.32	3-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol (commercially available)	3-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol; compound with formic acid	305.4
9.33	2-Methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol (Lit.: WO 0027853A1)	2-Methoxy-5-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol; compound with formic acid	335.4
9.34	2,6-Dimethoxy-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridine (Lit.: WO 9845265A1)	7-(2,6-Dimethoxy-pyridin-3-yl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	350.4

9.35	2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenol (Lit.: WO 0027853A1)	2-(2-Methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol; compound with formic acid	305.4
9.36	4,4,5,5-Tetramethyl-2-(4-phenoxy-phenyl)-[1,3,2]dioxaborolane (Lit.: WO 0027853A1)	2-Methyl-7-(4-phenoxy-phenyl)-4-pyrrolidin-1-yl-quinoline; compound with formic acid	381.5
9.37	2-(2,6-Dichloro-phenyl)-4,4,5,5-tetramethyl-[1,3,2]dioxaborolane (Lit.: J. Chromatogr. 1979, 186, 307-316)	7-(2,6-Dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline; compound with formic acid	358.3
9.38	3-Trifluoromethoxyboronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethoxy-phenyl)-quinoline; compound with formic acid	373.4
9.39	2-Trifluoromethoxyboronic acid (commercially available)	2-Methyl-4-pyrrolidin-1-yl-7-(2-trifluoromethoxy-phenyl)-quinoline; compound with formic acid	373.4

- 54 -

Example A

A compound of formula I can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:

	<u>Per tablet</u>
5 Active ingredient	200 mg
Microcrystalline cellulose	155 mg
Corn starch	25 mg
Talc	25 mg
Hydroxypropylmethylcellulose	<u>20 mg</u>
10	425 mg

Example B

A compound of formula I can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:

	<u>Per capsule</u>
Active ingredient	100.0 mg
Corn starch	20.0 mg
20 Lactose	95.0 mg
Talc	4.5 mg
Magnesium stearate	<u>0.5 mg</u>
	220.0 mg

25

EXAMPLE C

Tablets containing the following ingredients can be manufactured in a conventional manner:

<u>Ingredients</u>	<u>Per tablet</u>
Compound of formula I	10.0 - 100.0 mg
Lactose	125.0 mg
Maize starch	75.0 mg
Talc	4.0 mg
Magnesium stearate	1.0 mg

5

EXAMPLE D

Capsules containing the following ingredients can be manufactured in a conventional manner:

<u>Ingredients</u>	<u>Per capsule</u>
Compound of formula I	25.0 mg
Lactose	150.0 mg
Maize starch	20.0 mg
Talc	5.0 mg

10

15


EXAMPLE E

Injection solutions can have the following composition:

Compound of formula I	3.0 mg
Gelatine	150.0 mg
Phenol	4.7 mg
Water for injection solutions	ad 1.0 ml

Claims

1. Compounds of formula I



I

5 wherein

R^1 is alkyl, cycloalkyl, aralkyl or trifluoroalkyl;

R^2 is hydrogen, alkyl, alkoxy, hydroxy, halogen, trifluoroalkyl, difluoroalkoxy or trifluoroalkoxy;

R^3 is aryl or heteroaryl;

10 R^4 is hydrogen;

R^5 is hydrogen, alkyl or aralkyl;

R^6 and R^7 are each independently hydrogen or alkyl;

A^1 is CH or N;

A^2 is a 4- to 10- membered heterocyclic ring optionally substituted with alkyl, hydroxy, 15 alkoxy, alkoxyalkyl, alkoxyalkoxy, hydroxyalkoxy, $-COOR^5$ or $-CONR^6R^7$;

and pharmaceutically usable salts, solvates and esters thereof.

2. Compounds according to claim 1, wherein R^2 is hydrogen.

3. Compounds according to claim 1 or 2, wherein R^1 is alkyl.


4. Compounds according to claim 3, wherein R^1 is methyl.

5. Compounds according to any one of claims 1 to 4, wherein R³ is attached at the 7-position of the quinoline or quinazoline ring.
6. Compounds according to any one of claims 1 to 5, wherein A¹ is CH.
7. Compounds according to any one of claims 1 to 5, wherein A¹ is N.
- 5 8. Compounds according to any one of claims 1 to 7, wherein R³ is unsubstituted phenyl, thiophenyl, pyridinyl, pyrimidinyl, 1H-indolyl, benzofuryl, benzothiophenyl or naphthyl or R³ is phenyl, thiophenyl, pyridinyl, pyrimidinyl, 1H-indolyl, benzofuryl, benzothiophenyl or naphthyl, substituted with one to three substituents each independently selected from halogen, trifluoromethyl, amino, alkoxy, methylenedioxy, 10 alkylcarbonyl, cyano, alkyl, nitro, hydroxy, trifluoromethoxy, alkylsulfanyl, alkenyl, alkoxycarbonyl, aryloxy, alkoxycarbonylamino, alkylcarbonylamino and aminocarbonyl.
9. Compounds according to claim 8, wherein R³ is unsubstituted thiophenyl, pyridinyl or naphthyl or R³ is phenyl or thiophenyl substituted with one or two substituents each independently selected from halogen, trifluoromethyl, alkoxy, 15 alkylcarbonyl, cyano and hydroxy.
10. Compounds according to any one of claims 1 to 9, wherein A² is a 4- to 10-membered heterocyclic ring optionally substituted with alkyl.
11. Compounds according to claim 10, wherein A² is a pyrrolidine, piperidine, morpholine, piperazine, 3,4-dihydro-1H-isoquinoline or azepane ring, wherein these rings 20 are optionally substituted with alkyl.
12. Compounds in accordance with any one of claims 1 to 11, selected from
- 7-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
- 2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline;
- 1-[4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenyl]-ethanone;
- 25 7-(4-methoxy-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
- 2-methyl-4-pyrrolidin-1-yl-7-thiophen-2-yl-quinoline;
- 2-methyl-7-pyridin-3-yl-4-pyrrolidin-1-yl-quinoline;
- 2-methyl-4-piperidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinoline;

- 5-(3-chloro-phenyl)-2-methyl-4-piperidin-1-yl-quinoline;
 4-azepan-1-yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinoline;
 2-methyl-4-pyrrolidin-1-yl-7-(3-trifluoromethyl-phenyl)-quinazoline;
 7-(3-chloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinazoline;
 5 4-azepan-1-yl-2-methyl-7-(3-trifluoromethyl-phenyl)-quinazoline;
 3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-benzonitrile;
 1-[3-(2-methyl-4-pyrrolidin-1-yl-quinazolin-7-yl)-phenyl]-ethanone;
 7-(3-chloro-4-fluoro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
 1-[5-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-thiophen-2-yl]-ethanone;
 10 7-(3,4-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline;
 2-methoxy-4-(2-methyl-4-pyrrolidin-1-yl-quinolin-7-yl)-phenol;
 7-(3,5-dichloro-phenyl)-2-methyl-4-pyrrolidin-1-yl-quinoline and
 2-methyl-7-naphthalen-2-yl-4-pyrrolidin-1-yl-quinoline.

13. A process for the preparation of a compound according to any one of claims 1 to
 15 12, comprising one of the following reactions:

a) the reaction of a compound of formula



IIIa

in the presence of a compound of formula




IIa

20

or

b) the reaction of a compound of formula




in the presence of a compound of formula



wherein R^1 , R^2 , R^3 , R^4 , A^1 and A^2 are defined as in any one of claims 1 to 11 and Y and Z are substituents which can be used in transition metal catalysed cross coupling reactions.

14. Compounds of the formula X



- 10 wherein R^1 , R^2 , R^4 , A^1 and A^2 are defined as in any of claims 1 to 11 and, wherein R^9 is iodine, bromine, chlorine, methylsulfonyloxy, trifluoromethylsulfonyloxy, phenylsulfonyloxy or p-tosylsulfonyloxy.

15. Compounds in accordance with any one of claims 1 to 12 for use as therapeutically active substances.

- 15 16. Compounds in accordance with any one of claims 1 to 12 for the production of medicaments for the prophylaxis and therapy of illnesses which are caused by disorders associated with the NPY receptor.

17. A pharmaceutical composition containing a compound in accordance with any one of claims 1 to 12 and a therapeutically inert carrier.

18. The use of compounds in accordance with any one of claims 1 to 12 for the production of medicaments for the treatment and prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

19. Compounds in accordance with any one of claims 1 to 12, when manufactured
5 according to claim 13.

20. A method for the treatment and prophylaxis of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity, which method comprises administering an effective amount of a compound in accordance with any one of claims 1 to 12.

10 21. A method of treatment of obesity in a human in need of such treatment which comprises administration to the human a therapeutically effective amount of a compound according to any one of claims 1 to 12 and a therapeutically effective amount of a lipase inhibitor.

22. The method according to claim 21, wherein the lipase inhibitor is orlistat.

15 23. The method according to claims 21 and 22 for the simultaneous, separate or sequential administration.

24. The use of a compound according to any one of claims 1 to 12 in the manufacture of a medicament for the treatment and prevention of obesity in a patient who is also receiving treatment with a lipase inhibitor.

20 25. The use according to claim 24, wherein the lipase inhibitor is orlistat.

26. The pharmaceutical composition according to claim 17 comprising further a therapeutically effective amount of a lipase inhibitor.

27. The pharmaceutical composition according to claim 26, wherein the lipase inhibitor is orlistat.

25 28. The invention as hereinbefore described.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/20488 A3

(51) International Patent Classification⁷: C07D 215/42.
409/04, 401/04, 239/84, A61P 3/00, A61K 31/517,
31/4706

(21) International Application Number: PCT/EP01/10014

(22) International Filing Date: 30 August 2001 (30.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00119262.4 6 September 2000 (06.09.2000) EP

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]:
124 Grenzacherstrasse, CH-4070 Basle (CH).

(72) Inventors: BREU, Volker; 9a Leonhard-Mueller-Strasse,
79418 Schliengen (DE). DAUTZENBERG, Frank;
75 Vogesenstrasse, 79379 Muelheim (DE). GUERRY,
Philippe; In den Holeematten 2, CH-4102 Binningen
(CH). NETTEKOVEN, Matthias, Heinrich; Bandweg
10, 79639 Grenzach-Wyhlen (DE). PFLIEGER, Philippe;
1, rue du Vignoble, F-68130 Schwoben (FR).

(74) Agent: WITTE, Hubert; 124 Grenzacherstrasse,
CH-4070 Basle (CH).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).


Published:

— with international search report

(88) Date of publication of the international search report:
16 May 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINOLINE AND QUINAZOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR



(57) Abstract: Compounds of formula (I) as well as pharmaceutically usable salts, solvates and esters thereof, wherein R¹, R², R³, R⁴, A¹ and A² have the significance given in claim 1, can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis, cardiovascular diseases, diabetes, renal failure, eating disorders and obesity.

WO 02/20488 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 01/10014

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D215/42 C07D409/04 C07D401/04 C07D239/84 A61P3/00
A61K31/517 A61K31/4706

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 86 06721 A (ALKALOIDA VEGYESZETI GYAR) 20 November 1986 (1986-11-20) claim 2; example 1; table V ---	14
X	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KORODI, FERENC: "Nucleophilic substitution reaction of chloroquinolines with 1,2,4-triazole. I. Synthesis of 4-(1H-1,2,4-triazol-1-yl)quinolines" retrieved from STN Database accession no. 122:132333 XP002190201 compound with RN=160981-78-2 & HETEROCYCL. COMMUN. (1994), 1(1), 59-68 ' ---	14
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

14 February 2002

Date of mailing of the international search report

01/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/10014

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SAVINI, LUISA ET AL: "New 1-'quinolyl(4)!-1,2,3-triazoles: synthesis and evaluation of antiinflammatory and analgesic properties. II" retrieved from STN Database accession no. 122:71356 XP002190202 compounds with RN=160321-49-3; 160321-54-0; 160321-59-5; 160321-65-3; 160321-76-6; 160321-85-7 & FARMACO (1994), 49(10), 633-9 ,</p>	14
X	<p>----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SATHI, GARIMA ET AL: "New quinolines as potential CNS agents" retrieved from STN Database accession no. 99:175562 XP002190203 compounds with RN=87602-57-1; 87602-58-2; 87602-59-3 & ARCH. PHARM. (WEINHEIM, GER.) (1983), 316(9), 767-72 ,</p>	14
X	<p>----- DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; YAKHONTOV, L. N. ET AL: "Synthesis and study of the biological activity of substituted 4-amino-2-styrylquinazolines" retrieved from STN Database accession no. 84:43974 XP002190204 compounds with RN=57942-28-6; 57942-29-7; 57942-47-9; 57942-48-0 & KHIM.-FARM. ZH. (1975), 9(11), 12-18 ,</p>	14
A	<p>----- WO 97 09308 A (LILLY CO ELI) 13 March 1997 (1997-03-13) abstract</p>	1,15,16
P,X	<p>----- WO 01 02385 A (EMERIC GILBERT ;GARY STEPHANIE (FR); GERUSZ VINCENT (FR); HARTMANN) 11 January 2001 (2001-01-11) claims 1-5; examples</p> <p>-----</p>	14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/10014

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 8606721	A	20-11-1986	DD 245870 A5 HU 43838 A2 BG 47648 A3 BR 8606663 A DK 4187 A EP 0221947 A1 FI 870028 A ,B, FI 91065 B WO 8606721 A1 JP 6008292 B JP 62503030 T SU 1477247 A3 US 5104884 A AT 58731 T DE 3675889 D1	20-05-1987 28-12-1987 15-08-1990 11-08-1987 06-01-1987 20-05-1987 05-01-1987 31-01-1994 20-11-1986 02-02-1994 03-12-1987 30-04-1989 14-04-1992 15-12-1990 10-01-1991
WO 9709308	A	13-03-1997	AU 717422 B2 AU 6965096 A BR 9606619 A CA 2203912 A1 CN 1173867 A CZ 9701328 A3 EP 0789688 A1 HU 9701714 A2 JP 10508321 T NO 972016 A NZ 318228 A PL 320010 A1 TR 9700334 T1 WO 9709308 A1 US 6245761 B1	23-03-2000 27-03-1997 23-12-1997 13-03-1997 18-02-1998 12-11-1997 20-08-1997 28-06-1999 18-08-1998 17-06-1997 29-07-1999 01-09-1997 21-08-1997 13-03-1997 12-06-2001
WO 0102385	A	11-01-2001	FR 2795726 A1 AU 6288400 A WO 0102385 A1	05-01-2001 22-01-2001 11-01-2001